Glyxambi (Empagliflozin)
✅ Kontrollerer blodsukkerniveau
✅ Reducerer risikoen for hjertekarsygdomme
✅ Promotes weight loss
✅ Lowers blood pressure
✅ Improves kidney function
Glyxambi contains Empagliflozin & Linagliptin
✓ Medicinsk gennemgået af Morgan Ellis — Apoteksforsker · 8 års erfaring · Sidst gennemgået: maj 2026
⚡ Quick Answer — What is Glyxambi?
Glyxambi er en tablet med fast dosiskombination af empagliflozin (SGLT-2 inhibitor) og linagliptin (DPP-4 inhibitor) (Empagliflozin 10 or 25 mg + Linagliptin 5 mg) used for type 2-diabetes. It combines two non-insulinotropic mechanisms: empagliflozin causes the kidneys to excrete glucose in urine (for glycaemic, weight, BP, heart-failure, and kidney benefits), while linagliptin raises incretin hormones to stimulate glucose-dependent insulin release. Expected HbA1c reduction: 1.0–1.3 points — more than either component alone. Expected weight loss: 2–3 kg. Very low hypoglycaemia risk on its own. Once-daily dosing, with or without food. Main side effects: genital thrush, UTI, and rare DKA (empagliflozin); rare pancreatitis or arthralgia (linagliptin). Avoid in type 1 diabetes, DKA, eGFR < 30, and severe hepatic impairment.
📦 Hver ordre er dækket af vores Reshipment Assurance Policy — hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.
Hvorfor bestille fra MedsBase
Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomspændende i diskret, neutral emballage — ingen medicinnavn på pakkens ydre. Kortbetalinger håndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor — aldrig “MedsBase” eller medicinnavn). Crypto og SEPA bankoverførsel accepteres også. Hver ordre er dækket af vores Reshipment Assurance Policy.
What Is Glyxambi?
Glyxambi is a fixed-dose combination oral antidiabetic tablet containing two active ingredients: empagliflozin (SGLT-2 inhibitor) and linagliptin (DPP-4 inhibitor), in strengths of Empagliflozin 10 or 25 mg + Linagliptin 5 mg. Manufactured by Boehringer Ingelheim / Eli Lilly; available in packs of 30, 60, 90 or 180 tablets. It is prescribed for adults with type 2 diabetes — typically added to metformin, or initiated in patients with significant hyperglycaemia who would benefit from two non-insulinotropic mechanisms in a single tablet.
How Does Glyxambi Work?
The two components target hyperglycaemia through completely separate pathways — one insulin-independent, one incretin-based:
- Empagliflozin blocks SGLT-2 in the kidney proximal tubule, causing 70–90 g of glucose to be excreted in urine each day. This lowers blood glucose independently of insulin and also reduces weight (2–3 kg), blood pressure (3–5 mmHg), heart-failure hospitalisations (EMPEROR trials), and CKD progression (EMPA-KIDNEY).
- Linagliptin blocks the enzyme DPP-4, raising levels of the incretin hormones GLP-1 and GIP. This stimulates glukoseafhængig insulin release and suppresses glucagon — only when blood glucose is elevated. Linagliptin is unique among DPP-4 inhibitors in needing no renal dose adjustment.
Because neither component directly stimulates insulin release in a glucose-independent manner, Glyxambi has a very low hypoglycaemia risk on its own. Expected HbA1c reduction: 1.0–1.3 percentage points over either component alone.
Dosering og administration
Sædvanlig dosis: one tablet once daily in the morning, with or without food. The starting strength depends on prior therapy and glycaemic target.
- Glemt en dosis? Take as soon as you remember if it is within 12 hours; otherwise skip.
- Ren dosering: empagliflozin is limited to eGFR > 20 for HF/CKD indications (> 30 for glycaemic control); linagliptin needs no renal dose adjustment. The combination is typically avoided if eGFR < 30.
- Sick-day rules: pause during acute illness with vomiting, diarrhoea, or reduced oral intake (risk of euglycaemic DKA and AKI). Restart when eating and drinking normally.
- Do not start within 48 hours of major surgery or IV contrast.
Bivirkninger
Common (mostly from the empagliflozin component):
- Genital mycotic infections (thrush) — up to 10% of users
- Urinary tract infections
- Polyuria, mild dehydration, postural dizziness in the first 2 weeks
- Modest LDL-cholesterol rise
From the linagliptin component:
- Nasopharyngitis, headache, mild GI upset
Sjældne men vigtige:
- Diabetic ketoacidosis (DKA) — rare; can occur at near-normal blood glucose (“euglycaemic DKA”). Symptoms: nausea, vomiting, abdominal pain, deep breathing. Stop the drug and seek urgent care.
- Volume depletion, AKI — higher risk on diuretics or with acute illness
- Acute pancreatitis, severe arthralgia, bullous pemphigoid — rare DPP-4 class effects
- Fournier’s gangrene — extremely rare but serious
Lægemiddelinteraktioner
- Diuretics (loop and thiazide) — additive volume loss; consider diuretic dose reduction.
- Insulin, sulfonylureas, meglitinides — additive glucose-lowering; may need dose reduction to avoid hypoglycaemia.
- Rifampicin — reduces levels of both components.
- Antihypertensiva — additive BP-lowering.
Who Should Not Take Glyxambi?
- Type 1 diabetes mellitus
- Diabetic ketoacidosis — current or recent history
- Svært nedsat nyrefunktion (eGFR < 30)
- Severe volume depletion or hypotension
- Svær leversvigt
- Tidligere pankreatitis (relativ kontraindikation)
- Kendt overfølsomhed over for en af komponenterne
- Graviditet og amning
Opbevaring
Store Glyxambi below 30°C in a dry place. Keep out of reach of children.
Ofte stillede spørgsmål
Why combine an SGLT-2 inhibitor and a DPP-4 inhibitor in one tablet?
The two classes work by completely different mechanisms that do not overlap, so the HbA1c reduction of the combination is additive (1.0–1.3 points) rather than redundant. Both are weight-neutral to weight-favourable, and both have a very low hypoglycaemia risk, making the combination a good fit for patients who need additional glucose control without adding insulin or sulfonylurea risk.
Will Glyxambi help me lose weight?
Yes, modestly — typically 2–3 kg over 6–12 months. The weight loss comes from the empagliflozin component (urinary glucose excretion). Linagliptin is weight-neutral.
Does Glyxambi protect my heart and kidneys?
The empagliflozin component has strong evidence from EMPA-REG, EMPEROR-Reduced, EMPEROR-Preserved, and EMPA-KIDNEY trials for cardiovascular, heart failure, and kidney protection. Linagliptin is cardiovascular-neutral in CARMELINA. So the combination retains the empagliflozin cardio-renal benefits.
Will Glyxambi cause low blood sugar?
On its own, very rarely. Neither component stimulates insulin release in a glucose-independent manner. Hypoglycaemia becomes a concern when Glyxambi is combined with a sulfonylurea, meglitinide, or insulin.
What about thrush?
Genital thrush is the most common side effect (up to 10% of users, mostly women). It is usually mild and easily treated. Most patients do not need to stop Glyxambi.
Where can I buy Glyxambi online?
You can order Glyxambi (Empagliflozin 10 or 25 mg + Linagliptin 5 mg) from MedsBase in packs of 30, 60, 90 or 180 tablets. We ship worldwide, with discreet packaging and genuine WHO-GMP certified manufacturer stock.
Relaterede diabetesmedikamenter
- Jardiance — Empagliflozin monotherapy
- Trajenta — Linagliptin monoterapi
- Forxiga — Dapagliflozin (SGLT-2 alternativ)
- Januvia — Sitagliptin (DPP-4 alternative)
- Trajenta Duo — Linagliptin + Metformin
- Glycomet SR — Metformin med langsom frigivelse
- Se alle diabetesmedicin
Relaterede alternativer
Andre produkter inden for Kroniske tilstande som kunder også ser:
Flere muligheder inden for diabetes
Rangeret efter seneste MedsBase ordrevolumen — hvad andre kunder i denne kategori vælger.
| Styrke | 25mg/5mg |
|---|---|
| Antal | 10 Tablet/s, 30 Tablet/s, 60 Tablet/s, 90 Tablet/s |
Glyxambi (Empagliflozin)
Spørgsmål & svar
Glyxambi (Empagliflozin)
Relaterede produkter
Anmeldelser
Der er ingen anmeldelser endnu